AU2001244275A1 - Pneumococcus polysaccharide conjugates for use as vaccine against tetanus and diphtheria - Google Patents

Pneumococcus polysaccharide conjugates for use as vaccine against tetanus and diphtheria

Info

Publication number
AU2001244275A1
AU2001244275A1 AU2001244275A AU4427501A AU2001244275A1 AU 2001244275 A1 AU2001244275 A1 AU 2001244275A1 AU 2001244275 A AU2001244275 A AU 2001244275A AU 4427501 A AU4427501 A AU 4427501A AU 2001244275 A1 AU2001244275 A1 AU 2001244275A1
Authority
AU
Australia
Prior art keywords
diphtheria
vaccine against
polysaccharide conjugates
against tetanus
conjugated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001244275A
Inventor
Dominique Schulz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Pasteur SA
Original Assignee
AVENTIS PASTEUR
Aventis Pasteur SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8848189&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2001244275(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by AVENTIS PASTEUR, Aventis Pasteur SA filed Critical AVENTIS PASTEUR
Publication of AU2001244275A1 publication Critical patent/AU2001244275A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine

Abstract

The invention relates to the use of a composition comprising n Streptococcus pneumoniae polysaccharides conjugated to the tetanus toxoid and p Streptococcus pneumoniae polysaccharides conjugated to the diphtheria toxoid, for manufacturing a vaccine which protects against Clostridium tetani and/or Corynebacterium diphtheriae infections in which: (1) n and p are other than 1, with p being, however, <=15, (2) 2<=n+p<=38, (3) the total amount of conjugated toxoid present in one vaccine dose is sufficient to induce protection against Clostridium tetani and/or Corynebacterium diphtheriae infections.
AU2001244275A 2000-03-17 2001-03-19 Pneumococcus polysaccharide conjugates for use as vaccine against tetanus and diphtheria Abandoned AU2001244275A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0003407A FR2806304B1 (en) 2000-03-17 2000-03-17 POLYSACCHARIDIC CONJUGATES OF PNEUMOCOCCUS FOR VACCINE USE AGAINST TETANUS AND DIPHTHERIA
FR0003407 2000-03-17
PCT/FR2001/000820 WO2001068128A1 (en) 2000-03-17 2001-03-19 Pneumococcus polysaccharide conjugates for use as vaccine against tetanus and diphtheria

Publications (1)

Publication Number Publication Date
AU2001244275A1 true AU2001244275A1 (en) 2001-09-24

Family

ID=8848189

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001244275A Abandoned AU2001244275A1 (en) 2000-03-17 2001-03-19 Pneumococcus polysaccharide conjugates for use as vaccine against tetanus and diphtheria

Country Status (11)

Country Link
US (1) US20030099672A1 (en)
EP (1) EP1267922B1 (en)
AT (1) ATE297758T1 (en)
AU (1) AU2001244275A1 (en)
CA (1) CA2402807A1 (en)
DE (1) DE60111507T2 (en)
DK (1) DK1267922T3 (en)
ES (1) ES2240432T3 (en)
FR (1) FR2806304B1 (en)
PT (1) PT1267922E (en)
WO (1) WO2001068128A1 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2375704T5 (en) * 2000-06-29 2016-03-03 Smithkline Beecham Biologicals S.A. Composition of multivalent vaccine
SI1896065T2 (en) 2005-06-27 2014-12-31 Glaxosmithkline Biologicals S.A. Process for manufacturing vaccines
MY148141A (en) * 2005-12-22 2013-03-15 Glaxosmithkline Biolog Sa Vaccine
GB0607088D0 (en) * 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
EP2167120A2 (en) 2007-06-26 2010-03-31 GlaxoSmithKline Biologicals S.A. Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates
GB2495341B (en) * 2011-11-11 2013-09-18 Novartis Ag Fermentation methods and their products
KR102057217B1 (en) * 2012-06-20 2020-01-22 에스케이바이오사이언스 주식회사 Multivalent pneumococcal polysaccharide-protein conjugate composition
ITMI20121597A1 (en) * 2012-09-25 2014-03-26 Beta Pharma S A CONJUGATE BETWEEN FRAGRANCE OF BACTERIAL CELL WALL AND A MUCOPOLYSACCHARID VEHICLE AND ITS USES IN MEDICAL AREA
KR20140075196A (en) 2012-12-11 2014-06-19 에스케이케미칼주식회사 Multivalent pneumococcal polysaccharide-protein conjugate composition
JP2016502994A (en) * 2012-12-18 2016-02-01 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Conjugates to protect against diphtheria and / or tetanus
US9815886B2 (en) 2014-10-28 2017-11-14 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
MX2019001342A (en) * 2016-08-05 2019-07-04 Sanofi Pasteur Inc Multivalent pneumococcal polysaccharide-protein conjugate composition.
EA039427B1 (en) 2016-08-05 2022-01-26 Санофи Пастер Инк. Multivalent pneumococcal polysaccharide-protein conjugate composition
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
US10729763B2 (en) 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds
BR112019026192B1 (en) 2017-06-10 2022-05-10 Inventprise, Llc Multivalent conjugate vaccines with bivalent or multivalent conjugate polysaccharides that provide improved immunogenicity and avidity
SG11202006388SA (en) * 2018-02-05 2020-07-29 Sanofi Pasteur Inc Multivalent pneumococcal polysaccharide-protein conjugate composition
AU2019215212A1 (en) 2018-02-05 2020-07-23 Sk Bioscience Co., Ltd. Multivalent pneumococcal polysaccharide-protein conjugate composition
CN111989114A (en) 2018-04-18 2020-11-24 Sk生物科学株式会社 Capsular polysaccharides of streptococcus pneumoniae and immunogenic conjugates thereof
CN113607939A (en) * 2021-08-05 2021-11-05 艾美探索者生命科学研发有限公司 Method for measuring adsorption rate of various combined stock solutions of pneumococcal polysaccharide combined vaccine

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4619828A (en) * 1982-07-06 1986-10-28 Connaught Laboratories, Inc. Polysaccharide exotoxoid conjugate vaccines
US5204098A (en) * 1988-02-16 1993-04-20 The United States Of America As Represented By The Department Of Health And Human Services Polysaccharide-protein conjugates
US5153312A (en) * 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
FR2682388B1 (en) * 1991-10-10 1995-06-09 Pasteur Merieux Serums Vacc PROCESS FOR THE PREPARATION OF AN OLIGOSIDE BY DEPOLYMERIZATION OF A POLYOSIDE DERIVED FROM A PATHOGENIC AGENT, OLIGOSIDE THUS OBTAINED AND ITS USE IN PARTICULAR AS A VACCINE AGENT.
DK1090642T3 (en) * 1995-06-07 2008-09-22 Glaxosmithkline Biolog Sa Vaccines comprising a polysaccharide antigen carrier protein conjugate and free carrier protein
FR2763244B1 (en) * 1997-05-14 2003-08-01 Pasteur Merieux Serums Vacc MULTIVALENT VACCINE COMPOSITION WITH MIXED CARRIER
ATE421339T1 (en) * 1998-02-05 2009-02-15 Jackson H M Found Military Med SIMPLIFIED METHOD FOR FREE PROTEIN REMOVAL DURING PRODUCTION OF PROTEIN-POLYSACCHARIDE CONJUGATES AND VACCINES USING LIMITED PERMEABILITY MEDIA

Also Published As

Publication number Publication date
DK1267922T3 (en) 2005-10-17
US20030099672A1 (en) 2003-05-29
ES2240432T3 (en) 2005-10-16
CA2402807A1 (en) 2001-09-20
PT1267922E (en) 2005-09-30
DE60111507D1 (en) 2005-07-21
WO2001068128A1 (en) 2001-09-20
FR2806304B1 (en) 2002-05-10
EP1267922B1 (en) 2005-06-15
DE60111507T2 (en) 2006-05-11
ATE297758T1 (en) 2005-07-15
FR2806304A1 (en) 2001-09-21
EP1267922A1 (en) 2003-01-02

Similar Documents

Publication Publication Date Title
AU2001244275A1 (en) Pneumococcus polysaccharide conjugates for use as vaccine against tetanus and diphtheria
NZ595178A (en) Vaccine comprising Type 5 and Type 8 capsular polysaccharides from Staphyloccocus aureus
MY125387A (en) Vaccine
EA200901578A1 (en) VACCINE CONTAINING CONJUGATES OF CAPSULAR POLYSACCHARIDES STREPTOCOCCUS PNEUMONIAE
SG168517A1 (en) Pneumococcal polysaccharide conjugate vaccine
WO2002091998A3 (en) Novel meningitis conjugate vaccine
HU1000593D0 (en) Vaccine compositions
NZ598367A (en) Multiple vaccination including serogroup C meningococcus
MX358148B (en) Multivalent pneumococcal polysaccharide-protein conjugate composition.
NZ602682A (en) Multivalent meningococcal polysaccharide-protein conjugate vaccine
CY1110140T1 (en) Vaccination with Miningococcal conjugate
MX2020008198A (en) Multivalent pneumococcal polysaccharide-protein conjugate composition.
WO2010141312A3 (en) Flagellin fusion proteins and conjugates comprising pneumococcus antigens and methods of using the same
WO2001078787A3 (en) Lipopolysaccharide-conjugate vaccine for sepsis treatment
UA99703C2 (en) Use of streptococcus pneumoniae immunogenic composition
WO2000072803A3 (en) Streptococcus pneumoniae vaccine strain and uses thereof